A recent study reported that paclitaxel and trastuzumab administered after fluorouracil, epirubicin, and cyclophosphamide (FEC) and NAC for the treatment of HER2-positive early-stage breast cancer resulted in a high pCR rate. The gene discussed is ERBB2; the disease is breast cancer.